CAJ | 학술논문

目的：观察甘露聚糖肽胶囊用于老年慢性阻塞性肺疾病( COPD )稳定期的临床效果。方法将156例住院患者随机均分为试验组和对照组，各78例。在给予吸氧、平喘、解痉、抗感染（必要时）等常规治疗基础上，试验组给予甘露聚糖肽胶囊，对照组给予泛福舒，治疗后随访6个月。结果试验组COPD急性发作次数、发作持续天数均减少，但组间无显著性差异（ P﹥0.05）。治疗结束后，两组患者症状积分较治疗前均有改善（ P ﹤0.05），试验组改善更显著( P ﹤0.01)；治疗结束后，两组患者第1秒用力呼气量/用力肺活量（FEV1/FVC )、第1秒用力呼气量（FEV1）、第1秒用力呼气量占预计值百分比（FEV1％）均得到改善（ P﹤0.05），且试验组FEV1显著改善（ P﹤0.01）。试验组CD4＋，CD4＋/CD8＋，IgA及补体C3水平较治疗前均显著提高（ P﹤0.05），CD8＋显著降低（ P﹤0.05）；对照组IgA明显升高（ P﹤0.05），CD4＋，CD4＋/CD8＋及补体C3均较治疗前有所上升( P﹥0.05)，CD8＋无明显变化( P﹥0.05)；组间比较，治疗后试验组CD4＋，CD4＋/CD8＋及补体C3较对照组升高( P﹤0.05)，CD8＋显著降低( P﹤0.05)；两组IgA含量均升高，但差异无统计学意义（ P﹥0.05）。结论甘露聚糖肽胶囊能全面提高COPD患者的免疫功能，改善临床症状和肺功能。
목적：관찰감로취당태효낭용우노년만성조새성폐질병( COPD )은정기적림상효과。방법장156례주원환자수궤균분위시험조화대조조，각78례。재급여흡양、평천、해경、항감염（필요시）등상규치료기출상，시험조급여감로취당태효낭，대조조급여범복서，치료후수방6개월。결과시험조COPD급성발작차수、발작지속천수균감소，단조간무현저성차이（ P﹥0.05）。치료결속후，량조환자증상적분교치료전균유개선（ P ﹤0.05），시험조개선경현저( P ﹤0.01)；치료결속후，량조환자제1초용력호기량/용력폐활량（FEV1/FVC )、제1초용력호기량（FEV1）、제1초용력호기량점예계치백분비（FEV1％）균득도개선（ P﹤0.05），차시험조FEV1현저개선（ P﹤0.01）。시험조CD4＋，CD4＋/CD8＋，IgA급보체C3수평교치료전균현저제고（ P﹤0.05），CD8＋현저강저（ P﹤0.05）；대조조IgA명현승고（ P﹤0.05），CD4＋，CD4＋/CD8＋급보체C3균교치료전유소상승( P﹥0.05)，CD8＋무명현변화( P﹥0.05)；조간비교，치료후시험조CD4＋，CD4＋/CD8＋급보체C3교대조조승고( P﹤0.05)，CD8＋현저강저( P﹤0.05)；량조IgA함량균승고，단차이무통계학의의（ P﹥0.05）。결론감로취당태효낭능전면제고COPD환자적면역공능，개선림상증상화폐공능。
Objective To observe the clinical efficacy of Mannatide Capsules in the treatment of elderly patients with stable stage of chronic obstructive pulmonary disease ( COPD ) . Methods 156 inpatients with COPD were randomly divided into the experimental group ( n=78 ) and the control group ( n=78 ) . On the basis of the conventional therapy such as oxygen inhalation, relieving asthma, spasmoly-sis and anti-infection ( in necessity ) , the experimental group was administrated with Mannatide Capsules and the control group was given Broncho-vaxom. The follow up lasted for 6 months after therapy. Results The experimental group had less frequency and short onset persistent duration of AECOPD than the control group, but without statistically significant difference between the two groups ( P ﹥0. 05 );the symptom scores after treatment in the two groups were improved compared with those before treatment ( P ﹤ 0. 05 ) , but the efficacy of the experimental group was more significant than that of the control group ( P ﹤ 0. 01 );FEV1/FVC, FEV1 and FEV1% after treatment in the two groups were improved compared with those before treatment ( P ﹤ 0. 05 ) , moreover FEV1 in the experiment group was improved significantly ( P ﹤ 0. 01 ) . the levels of CD3 +CD4 +, CD3+CD4 + /CD3+CD8 +, IgA and C3 after treatment in the experiment group were significantly improved than those before treatment ( P ﹤ 0. 05 ) , and the CD3 +CD8 + level was significantly decreased ( P ﹤0. 05 ); the IgA level in the control group was significantly increased ( P ﹤ 0. 05 ) , and the levels of CD3 +CD4+, CD3 +CD4+ /CD3 +CD8+and C3 were increased than those before treatment ( P ﹥ 0. 05 ) , while the CD3 +CD8 + level had no obvious difference ( P ﹥ 0. 05 );com-pared with the control group, the levels of CD3+CD4 +, CD3 +CD4+ /CD3+CD8 + and C3 in the experiment group were significant increased ( P ﹤ 0. 05 ) and the CD3+CD8 + level was significantly decreased ( P ﹤ 0. 05 ) , while the IgA level in the two groups were increased, but the difference was not statistically significant ( P ﹥ 0. 05 ) . Conclusion Mannatide Capsules can all-roundly improve the immune function, improve the clinical symptoms and lung function, in the patients with COPD.